In only one case, where, upon secondary comprehensive review an initial diagnosis of NSCLC was updated to RCC, was an FDA-approved therapy lost, in the setting of a MET exon 14 skipping alteration (Fig. 2, case 22). This evidence concerns the gene MET and non-small cell lung carcinoma.